Form 4: Dianthus Therapeutics, Inc. /DE/ Director Sells Shares
Insider Transaction (Form 4)
Anne Mcgeorge, a Director of Dianthus Therapeutics, Inc. /DE/, sold 7,750 shares of common stock on August 10, 2026.
Summary
- Option exercise/conversion: acquired 1,250 Common Stock at $19.36 ($24,200) on August 10, 2026; holds 1,250 after (Direct).
- Option exercise/conversion: acquired 6,500 Common Stock at $11.20 ($72,800) on August 10, 2026; holds 7,750 after (Direct).
- Open-market sale: disposed of 1,450 Common Stock at $107.58 ($155,991) on August 10, 2026; holds 6,300 after (Direct).
- Open-market sale: disposed of 2,800 Common Stock at $108.38 ($303,464) on August 10, 2026; holds 3,500 after (Direct).
- Open-market sale: disposed of 1,800 Common Stock at $109.30 ($196,740) on August 10, 2026; holds 1,700 after (Direct).
- Open-market sale: disposed of 1,000 Common Stock at $110.64 ($110,640) on August 10, 2026; holds 700 after (Direct).
- Open-market sale: disposed of 700 Common Stock at $111.41 ($77,987) on August 10, 2026 (Direct).
- Option exercise/conversion: disposed of 1,250 Stock Option (Right to Buy) on August 10, 2026 (Direct).
- Option exercise/conversion: disposed of 6,500 Stock Option (Right to Buy) on August 10, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $844,822 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Anne Mcgeorge — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Option exercise/conversion | Common Stock | 1,250 | $19 | $24.2K | 1,250 |
| 2026-08-10 | Option exercise/conversion | Common Stock | 6,500 | $11 | $72.8K | 7,750 |
| 2026-08-10 | Open-market sale | Common Stock | 1,450 | $108 | $156.0K | 6,300 |
| 2026-08-10 | Open-market sale | Common Stock | 2,800 | $108 | $303.5K | 3,500 |
| 2026-08-10 | Open-market sale | Common Stock | 1,800 | $109 | $196.7K | 1,700 |
| 2026-08-10 | Open-market sale | Common Stock | 1,000 | $111 | $110.6K | 700 |
| 2026-08-10 | Open-market sale | Common Stock | 700 | $111 | $78.0K | 0 |
| 2026-08-10 | Option exercise/conversion | Stock Option (Right to Buy) | 1,250 | — | — | 0 |
| 2026-08-10 | Option exercise/conversion | Stock Option (Right to Buy) | 6,500 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Option exercise/conversion (1,250 shares) |
| 2026-08-10 | Option exercise/conversion (6,500 shares) |
| 2026-08-10 | Open-market sale (1,450 shares) |
| 2026-08-10 | Open-market sale (2,800 shares) |
| 2026-08-10 | Open-market sale (1,800 shares) |
| 2026-08-10 | Open-market sale (1,000 shares) |
| 2026-08-10 | Open-market sale (700 shares) |
| 2026-08-10 | Option exercise/conversion (1,250 shares) |
| 2026-08-10 | Option exercise/conversion (6,500 shares) |
Keywords
insider transaction, Form 4, DNTH, Dianthus Therapeutics, Inc. /DE/, bearish, Anne Mcgeorge
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.